Capricor Therapeutics, Inc. (CAPR)
| Market Cap | 344.76M +18.4% |
| Revenue (ttm) | n/a |
| Net Income | -129.42M |
| EPS | -2.47 |
| Shares Out | 58.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,450,350 |
| Open | 6.03 |
| Previous Close | 6.13 |
| Day's Range | 5.80 - 6.08 |
| 52-Week Range | 2.96 - 40.37 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 27.00 (+355.31%) |
| Est. Earnings | Nov 9, 2026 |
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CAPR stock is "Buy." The 12-month stock price target is $27.0, which is an increase of 355.31% from the latest price.
News
Capricor Therapeutics Transcript: Study result
HOPE-3 and pooled HOPE-2/HOPE-3 analyses showed preservation of upper-limb function, with OLE data supporting sustained effects. Cardiac findings and safety follow-up were also presented ahead of the Nov. 22 PDUFA date.
Capricor Therapeutics Press release: Study result
Capricor Therapeutics issued a press release on October 7, 2026, disclosing material business information to investors.
Capricor Therapeutics Slides: Study result
Capricor Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 7, 2026.
Capricor Therapeutics call buyer realizes 94% same-day gains
Notable profits for the buyer who lifted the $0.56 offer for 2,768 Capricor Therapeutics (CAPR) 11/13 weekly 10 calls yesterday at 15:28ET when underlying shares were trading at $7.72. Shares…
Roth sees second FDA panel as possibility for Capricor
Roth Capital believes Capricor Therapeutics (CAPR)’ open label extension data this morning strengthens deramiocel’s upper-limb efficacy. However, early-start separation was modest, safety disclosure w...
H.C. Wainwright sees complete response letter as most likely for Capricor
H.C. Wainwright views Capricor Therapeutics (CAPR)’ 24-month open-label extension data as “encouraging,” with slower modeled PUL 2.0 decline after placebo patients crossed over to deramiocel. The data...
Capricor announces open-label extension data for Deramiocel
Capricor Therapeutics (CAPR) this morning announced new data from its ongoing HOPE-3 open-label extension study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne m...
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline...
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (CAPR) Investors to Their Right to Seek Lead Plaintiff Status Before September 29, 2026
New York, New York--(Newsfile Corp. - September 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Com...
Kaplan Fox Urges Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Seek a Leadership Role Before September 28, 2026
NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:...
Kaplan Fox & Kilsheimer LLP Encourages Investors of Capricor Therapeutics, Inc. (CAPR) to Contact the Firm Ahead of the Lead Plaintiff Deadline on September 29, 2026
New York, New York--(Newsfile Corp. - September 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Com...
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:...
$CAPR Stock Notification: Capricor Therapeutics has been Sued for Securities Fraud after Clinical Data Issues Disclosed – Investors are Alerted to Contact BFA Law by September 28
Capricor Therapeutics has been Sued for Securities Fraud after Clinical Data Issues Disclosed – Investors are Alerted to Contact BFA Law by September 28
SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline
Philadelphia, Pennsylvania--(Newsfile Corp. - September 22, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR)...
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline
SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Caprico...
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN ...
Kaplan Fox Advises Investors of Capricor Therapeutics, Inc. (CAPR) to Contact the Firm Before the Deadline on September 28, 2026
New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Com...
Capricor Therapeutics upgraded to Buy from Neutral at B. Riley
B. Riley analyst Madison El-Saadi upgraded Capricor Therapeutics (CAPR) to Buy from Neutral with a price target of $21, up from $5. The share setup is favorable into the November…
Kaplan Fox Encourages Capricor Therapeutics, Inc. (CAPR) Investors Who Suffered Losses to Seek a Leadership Role Before September 28, 2026
New York, New York--(Newsfile Corp. - September 11, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Com...
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to an Approaching Lead Plaintiff Deadline on September 28, 2026
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:...
LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation
SAN DIEGO--(BUSINESS WIRE)--The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares in the U.S. District Court f...
Capricor Therapeutics (NASDAQ:CAPR) Shares Fall 64% Following Clinical Data Disclosure -- Investors with Losses Notified to Contact BFA Law before September 28 Deadline
NEW YORK, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CA...
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (CAPR) to Act Ahead of the Lead Plaintiff Deadline on September 28, 2026
New York, New York--(Newsfile Corp. - September 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Comp...
Kaplan Fox Notifies Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the Lead Plaintiff Deadline on September 28, 2026
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:...